A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity

Demonstrating biosimilarity entails comprehensive analytical assessment, clinical pharmacology profiling, and efficacy testing in patients for at least one medical indication, as required by the U.S. Biologics Price Competition and Innovation Act (BPCIA). The efficacy testing can be waived if the dr...

Descripción completa

Detalles Bibliográficos
Autor principal: Niazi, Sarfaraz K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675618/
https://www.ncbi.nlm.nih.gov/pubmed/38004421
http://dx.doi.org/10.3390/ph16111556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675618/
https://www.ncbi.nlm.nih.gov/pubmed/38004421
http://dx.doi.org/10.3390/ph16111556

Ejemplares similares